Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2009;54:63-70
Published online before print May 11, 2009, doi: 10.1161/HYPERTENSIONAHA.109.129098
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
54/1/63    most recent
HYPERTENSIONAHA.109.129098v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Caton, A. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caton, A. R.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Blood Pressure Medicines
*High Blood Pressure
*High Risk Pregnancy
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Cardiac development
Right arrow Epidemiology

(Hypertension. 2009;54:63.)
© 2009 American Heart Association, Inc.


Original Articles

Antihypertensive Medication Use During Pregnancy and the Risk of Cardiovascular Malformations

Alissa R. Caton; Erin M. Bell; Charlotte M. Druschel; Martha M. Werler; Angela E. Lin; Marilyn L. Browne; Louise-Anne McNutt; Paul A. Romitti; Allen A. Mitchell; Richard S. Olney; Adolfo Correa for the National Birth Defects Prevention Study

From the Department of Epidemiology and Biostatistics (A.R.C., E.M.B., C.M.D., M.L.B., L.-A.M.), School of Public Health, University at Albany, Rensselaer, NY; Congenital Malformations Registry (A.R.C., C.M.D., M.L.B.), New York State Department of Health, Troy; Slone Epidemiology Center (M.M.W., A.A.M.), Boston University, Mass; Genetics Unit (A.E.L.), MassGeneral Hospital for Children, Boston; Department of Epidemiology (P.A.R.), College of Public Health, University of Iowa, Iowa City; and the National Center on Birth Defects and Developmental Disabilities (R.S.O., A.C.), Centers for Disease Control and Prevention, Atlanta, Ga.

Correspondence to Alissa R. Caton, New York State Department of Health, Bureau of Environmental and Occupational Epidemiology, 547 River St, Room 200, Troy, NY 12180-2216. E-mail arc05{at}health.state.ny.us

We used data from the National Birth Defects Prevention Study, a population-based, case-control study, to examine whether previously reported associations between antihypertensive medications and cardiovascular malformations could be confirmed and to explore whether new associations might be identified. Cases (n=5021) were ascertained through birth defects surveillance systems from 1997 through 2003 in 10 US states. Controls (n=4796) were live births without birth defects selected randomly from birth certificates or hospital discharge listings in the same geographic regions. Logistic regression was used to examine the relationship between antihypertensive medication treatment and the occurrence of cardiovascular malformations while controlling for confounding variables. First-trimester treatment with antihypertensive medication was associated with pulmonary valve stenosis (odds ratio [OR]: 2.6; 95% CI: 1.3 to 5.4), Ebstein malformation (crude OR: 11.4; exact 95% CI: 2.8 to 34.1), coarctation of the aorta (OR: 3.0; 95% CI: 1.3 to 6.6), and secundum atrial septal defects (OR: 2.4; 95% CI: 1.3 to 4.4). Treatment initiated after the first trimester was associated with pulmonary valve stenosis (OR: 2.4; 95% CI: 1.1 to 5.4), perimembranous ventricular septal defects (OR: 2.3; 95% CI: 1.2 to 4.6), and secundum atrial septal defects (OR: 2.4; 95% CI: 1.3 to 4.4). Untreated hypertension was associated with Ebstein malformation (OR: 2.1; 95% CI: 1.0 to 4.3) and secundum atrial septal defects (OR: 1.3; 95% CI: 1.0 to 1.6). Antihypertensive medication use and/or the underlying hypertension might increase the risk of having an infant with specific left and right obstructive and septal defects. Additional studies with adequate power will be needed to confirm these findings.


Key Words: hypertension • pregnancy • antihypertensive agents • congenital malformations • cardiovascular malformations




This article has been cited by other articles:


Home page
QJMHome page
O. Jolobe
Comments have special relevance for pregnant patients on haemodialysis
QJM, December 1, 2009; 102(12): 889 - 890.
[Full Text] [PDF]